Catheter Precision, Inc. (VTAK) — SEC Filings
Catheter Precision, Inc. (VTAK) — 50 SEC filings. Latest: 8-K (Nov 21, 2025). Includes 34 8-K, 4 10-Q, 2 DEF 14A.
View Catheter Precision, Inc. on SEC EDGAR
Overview
Catheter Precision, Inc. (VTAK) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 21, 2025: Catheter Precision, Inc. announced on November 17, 2025, the termination of a material definitive agreement. The company, formerly known as Ra Medical Systems, Inc., filed this 8-K report to disclose this event. No specific details regarding the agreement or the counterparty were provided in the fil
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 45 neutral, 2 mixed. The dominant filing sentiment for Catheter Precision, Inc. is neutral.
Filing Type Overview
Catheter Precision, Inc. (VTAK) has filed 34 8-K, 4 10-Q, 2 DEF 14A, 1 DEFA14A, 1 10-K/A, 1 10-K, 1 S-1, 2 SC 13G/A, 1 8-K/A, 1 SC 13G, 1 SC 13D, 1 S-1/A with the SEC between Jun 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of VTAK's 46 recent filings, 3 were flagged as high-risk, 25 as medium-risk, and 18 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $226K |
| Net Income | $(2.25M) |
| Cash Position | $1.08M |
| Total Assets | $25.47M |
| Total Debt | $19.02M |
Key Executives
- David A. Jenkins
- Philip Anderson
- Dr. David L. Smith
- Ms. Jennifer L. Smith
- Dr. David R. D. Smith
- Mr. David M. Smith
- Mr. Mark J. Smith
- Dr. David E. Leo
- Dr. Robert L. Smith
- David Jenkins
- Jenkins Casey A.
- Mr. Jenkins
- Dr. David L. Chen
- Mr. Robert L. Lerman
- Mr. Charles R. Martin
Industry Context
The medical device industry, particularly in electrophysiology, is characterized by rapid technological innovation, significant R&D investment, and a complex regulatory landscape. Companies like Catheter Precision compete with established players and emerging startups, requiring continuous product development and market penetration strategies. Reimbursement policies and physician adoption rates are critical factors for success.
Top Tags
filing (7) · corporate-action (6) · material-agreement (6) · 8-K (5) · amendment (5) · equity-sale (5) · financials (4) · sec-filing (4) · material-definitive-agreement (4) · regulatory-filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue for Q3 2025 | $226K | Increased from $96K in Q3 2024, a 135% increase. |
| Revenue for nine months ended Sept 30, 2025 | $581K | Increased from $271K in the same period of 2024. |
| Net loss attributable to Catheter Precision, Inc. for Q3 2025 | $(2.25M) | Improved from $(4.12M) in Q3 2024. |
| Net loss attributable to Catheter Precision, Inc. for nine months ended Sept 30, 2025 | $(11.41M) | Slightly higher than $(11.02M) in the same period of 2024. |
| Cash and cash equivalents as of Sept 30, 2025 | $1.08M | Decreased from $2.87M at Dec 31, 2024. |
| Total liabilities as of Sept 30, 2025 | $19.02M | Increased from $16.01M at Dec 31, 2024. |
| Reverse stock split ratio | 1-for-19 | Effective August 15, 2025. |
| Proceeds from ATM offering | $3.74M | Net of issuance costs for the nine months ended Sept 30, 2025. |
| SEC File Number | 001-38677 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 38-3661826 | Company's tax identification number. |
| Current authorized common stock shares | 60 million | Proposed to increase to 500 million shares |
| Proposed authorized common stock shares | 500 million | Represents a 733% increase from current authorization |
| Shares of Common Stock issued and outstanding | 1,487,266 | As of the September 10, 2025 record date |
| Holders of record | 74 | As of the September 10, 2025 record date |
| Date of Special Meeting | October 10, 2025 | Stockholders will vote on proposals |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Catheter Precision, Inc. (VTAK)?
Catheter Precision, Inc. has 50 recent SEC filings from Jun 2024 to Nov 2025, including 34 8-K, 4 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of VTAK filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 45 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Catheter Precision, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Catheter Precision, Inc. (VTAK) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Catheter Precision, Inc.?
Key financial highlights from Catheter Precision, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for VTAK?
The investment thesis for VTAK includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Catheter Precision, Inc.?
Key executives identified across Catheter Precision, Inc.'s filings include David A. Jenkins, Philip Anderson, Dr. David L. Smith, Ms. Jennifer L. Smith, Dr. David R. D. Smith and 11 others.
What are the main risk factors for Catheter Precision, Inc. stock?
Of VTAK's 46 assessed filings, 3 were flagged high-risk, 25 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Catheter Precision, Inc.?
Forward guidance and predictions for Catheter Precision, Inc. are extracted from SEC filings as they are enriched.